Mumbai, January 31, 2025 – Pfizer Limited (BSE: 500680, NSE: PFIZER) has announced its unaudited financial results for the quarter and nine months ended December 31, 2024.
Financial Highlights (₹ in Crores)
| Particulars | Q3 FY2025 | Q2 FY2025 | Q3 FY2024 | 9M FY2025 | 9M FY2024 | FY2024 (Audited) |
|---|---|---|---|---|---|---|
| Revenue from Operations | 537.99 | 588.59 | 539.97 | 1,689.44 | 1,646.54 | 2,193.17 |
| Other Income | 42.76 | 43.07 | 35.85 | 127.67 | 105.38 | 180.51 |
| Total Income | 580.75 | 631.66 | 575.82 | 1,817.11 | 1,751.92 | 2,373.68 |
| Total Expenses | 408.31 | 416.43 | 407.83 | 1,226.82 | 1,257.66 | 1,635.56 |
| Profit Before Tax | 172.44 | 215.23 | 167.99 | 590.29 | 502.21 | 746.07 |
| Net Profit | 127.06 | 157.82 | 129.98 | 436.66 | 372.47 | 551.33 |
| Earnings Per Share (EPS) (₹) | 27.89 | 34.61 | 28.42 | 95.44 | 81.42 | 120.51 |
Segment-Wise Performance
Pfizer Limited continues to operate in a single segment, Pharmaceuticals, and has reported consistent growth in revenue and profitability over the nine-month period. The increase in revenue was driven by strong sales across key product categories, while cost control measures helped maintain profitability.Key Financial Developments & Exceptional Items
- VAT/CST Litigation Resolution: The company had previously recorded an exceptional gain in FY2024 due to excess provision write-back under the Maharashtra VAT Amnesty Scheme. No such exceptional gains were reported in Q3 FY2025.
- Sale of Thane MIDC Property: Pfizer entered into an agreement with Zoetis Pharmaceutical Research Private Limited for the transfer of leasehold rights and sale of buildings at its Thane facility for ₹264.40 crore. An advance of ₹52.88 crore has been received, but the transaction is pending MIDC approval.
Management Commentary
Meenakshi Nevatia, Managing Director, Pfizer Limited, stated:"Our performance in Q3 FY2025 reflects continued resilience and strategic focus in the Indian pharmaceutical market. Despite macroeconomic challenges, we have maintained robust revenue growth and profitability, driven by our strong product portfolio and operational efficiencies. We remain committed to driving sustainable long-term growth."
Outlook & Future Strategy
- The company expects stable revenue growth supported by strong demand for key therapeutic products.
- Expansion efforts and digital transformation initiatives are underway to enhance operational efficiency.
- Ongoing regulatory approvals, including the Thane MIDC property sale, will influence financial performance in the coming quarters.